Skip to main content
Premium Trial:

Request an Annual Quote

Adam Sachs, David Weber

Premium
Lentigen has named Adam Sachs to the newly created position of president of commercial operations, where he will lead efforts to market the firm’s lentiviral platform, the company said.
 
Sachs comes to Lentigen having spent 15 years in the biotech field, most recently as a molecular biology product development executive at Life Technologies, which is now Invitrogen.
 
Sachs also was director of manufacturing at Qiagen and vice president of operations at OriGene Technologies.
 

 
The Analytical and Life Science Systems Association, a trade group for product makers and marketers in the life sciences, has appointed Eksigent president and CEO David Weber to its board of directors, Eksigent said.
 
Before joining Eksigent Weber served as vice president of global marketing and business development for Stratagene and was president of the Americas at Amersham Biosciences.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.